Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxybutynin Vaginal Ring for Overactive Bladder (DR-OXY-302)
NCT00782769Phase 3Completed
- Sponsor
- Duramed Research
- Start
- Sep 2008
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of DR-3001 in overactive bladder (OAB) (2 arms), sponsored by Duramed Research. Primary endpoint: Safety and Tolerability at 42 weeks. Started Sep 2008; status: completed.
02
Drugs
DR-3001
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00782769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00782769.